These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 18268073

  • 21. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 22. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 23. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH, Masoodi SR, Laway BA, Wani AI, Bashir MI.
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [Abstract] [Full Text] [Related]

  • 24. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG.
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [Abstract] [Full Text] [Related]

  • 25. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
    Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E.
    Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
    [Abstract] [Full Text] [Related]

  • 26. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin.
    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.
    Diabetes Care; 2006 Aug; 29(8):1818-25. PubMed ID: 16873786
    [Abstract] [Full Text] [Related]

  • 27. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG, Gebbie J, Home PD.
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [Abstract] [Full Text] [Related]

  • 28. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M.
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [Abstract] [Full Text] [Related]

  • 29. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
    Cucinotta D, Russo GT.
    Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
    [Abstract] [Full Text] [Related]

  • 30. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 31. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 32. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA, Perez A, Zhang J, Pioglitazone 343 Study Group.
    Diabetes Obes Metab; 2006 Mar 05; 8(2):164-74. PubMed ID: 16448520
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W, Ersoy C, Wang G, Ye S, Liu J, Miao H, Asirvatham A, Werther S, Kadu P, Chow F.
    Diabetes Res Clin Pract; 2019 Apr 05; 150():158-166. PubMed ID: 30872064
    [Abstract] [Full Text] [Related]

  • 34. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Apr 05; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 35. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial.
    Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G.
    J Diabetes Investig; 2016 Jan 05; 7(1):85-93. PubMed ID: 26816605
    [Abstract] [Full Text] [Related]

  • 36. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May 05; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar 05; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 38. Study design and baseline characteristics of patients in the PRESENT study.
    Shestakova M, Bech OM, Momani MS.
    Diabetes Res Clin Pract; 2008 Sep 05; 81 Suppl 1():S3-9. PubMed ID: 18672309
    [Abstract] [Full Text] [Related]

  • 39. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan 05; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 40. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan 05; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.